AMT-130 Four-Year Update Complicates a Stronger 36-Month Case
uniQure reported new 48-month data for ifezuntirgene inilparvovec, formerly AMT-130, in early manifest Huntington disease. Among 12 high-dose patients, cUHDRS decline was 44% slower than an updated propensity-matched external control but was not statistically…
